Nanobiotix Provides Second Quarter Operational and Financial Update sharewise.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sharewise.com Daily Mail and Mail on Sunday newspapers.
NANOBIOTIX Announces First Quarter Operational and Financial Updates
Expanded clinical data set supporting tumor agnostic potential of NBTXR3 in presentation of first results in rectal cancer at ASCO-GI 2021
Initiated new combination study evaluating NBTXR3 activated by radiation in combination with chemotherapy in esophageal cancer and reported new preclinical data in immunotherapy at AACR RSM 2021, providing further support for radioenhancer NBTXR3 as a therapeutic combination-agnostic that could prime adaptive immune response for local and systemic control
New collaboration agreement signed by subsidiary Curadigm with Sanofi evaluating novel Nanoprimer technology in gene therapy
Cash, cash equivalents, and short-term investments were €107.1 million at March 31, 2021, continuing to support robust development plans into the second quarter of 2023
NANOBIOTIX and PharmaEngine Mutually Agree to Conclude Collaboration
PARIS & CAMBRIDGE, Mass. (BUSINESS WIRE) Regulatory News:
NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘
Company’’), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that the Company has reached an agreement with PharmaEngine, Inc. (“PharmaEngine”) to terminate the License and Collaboration agreement that the Company and PharmaEngine entered into in August 2012.
As previously disclosed in the Nanobiotix prospectus filed with the U.S. Securities and Exchange Commission on December 11, 2020, in November 2020, Nanobiotix notified PharmaEngine of a material breach of the terms of the License and Collaboration agreement. In a letter dated December 1, 2020, PharmaEngine responded to the Company’s notification of material breach, denying a material breach of the Licens
The agreement provided PharmaEngine exclusive rights to further the development of NBTXR3 in the Asia-Pacific region.
Nanobiotix filed a prospectus last year notifying PharmaEngine of a material breach of the terms of the agreement.
PharmaEngine denied any breach and asserted certain material breaches of that agreement by Nanobiotix.
Pursuant to this termination, Nanobiotix will retain all rights to the development and commercialization of NBTXR3 in the Asia-Pacific region.
PharmaEngine will receive payments not exceeding $5 million in total.
In the future, PharmaEngine will be entitled to receive a payment of $7.5 million upon a second regulatory approval of NBTXR3.
If NBTX announces a new collaboration for the Asia-Pacific region within six months of the agreement s effective date, PharmaEngine will be entitled to an immediate $2.5 million payment.
PARIS & CAMBRIDGE, Mass. (BUSINESS WIRE) March 4, 2021 Regulatory News: NANOBIOTIX (Euronext : NANO NASDAQ: NBTX - the
Company ), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that the Company has reached an agreement with PharmaEngine, Inc. ( PharmaEngine ) to terminate the License and Collaboration agreement that the Company and PharmaEngine entered into in August 2012. As previously disclosed in the Nanobiotix prospectus filed with the U.S. Securities and Exchange Commission on December 11, 2020, in November 2020, Nanobiotix notified PharmaEngine of a material breach of the terms of the License and Collaboration agreement. In a letter dated December 1, 2020, PharmaEngine responded to the Company s notification of material breach, denying a material breach of the License and Collaboration agreement, and asserting certain material brea